Composition for prophylaxis or treatment of il-8 related diseases

Patent metadata

Field	Value
Publication number	US-2024083996-A1
Application number	US-202318450863-A
Country	US
Kind code	A1
Filing date	Aug 16, 2023
Priority date	Aug 5, 2016
Publication date	Mar 14, 2024
Grant date	—

Abstract

For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.

First claim

1 - 15 . (canceled)

16 . A method for treating an IL-8-related disease, which comprises administering an anti-IL-8 antibody that binds to human IL-8 to a subject in need thereof,
wherein the IL-8-related disease is selected from chronic obstructive pulmonary disease (COPD), cystic fibrosis, psoriasis, hepatic fibrosis, renal fibrosis, and pulmonary fibrosis, and wherein the anti-IL-8 antibody comprises: (a) the amino acid sequence of SEQ ID NO: 23 as HVR-H1, (b) the amino acid sequence of SEQ ID NO: 29 as HVR-H2, (c) the amino acid sequence of SEQ ID NO: 30 as HVR-H3, (d) the amino acid sequence of SEQ ID NO: 26 as HVR-L1, (e) the amino acid sequence of SEQ ID NO: 31 as HVR-L2, and (f) the amino acid sequence of SEQ ID NO: 32 as HVR-L3.

17 . The method of claim 16 , wherein the anti-IL-8 antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 34 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 35.

18 . The method of claim 17 , wherein the anti-IL-8 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 36 and a light chain comprising the amino acid sequence of SEQ ID NO: 38.

19 . The method of claim 17 , wherein the anti-IL-8 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 37 and a light chain comprising the amino acid sequence of SEQ ID NO: 38.

20 . The method of claim 16 , wherein the disease is COPD.

21 . The method of claim 16 , wherein the disease is cystic fibrosis.

22 . The method of claim 16 , wherein the disease is psoriasis.

23 . The method of claim 16 , wherein the disease is hepatic fibrosis.

24 . The method of claim 16 , wherein the disease is renal fibrosis.

25 . The method of claim 16 , wherein the disease is pulmonary fibrosis.

26 . The method of claim 17 , wherein the disease is COPD.

27 . The method of claim 17 , wherein the disease is cystic fibrosis.

28 . The method of claim 17 , wherein the disease is psoriasis.

29 . The method of claim 17 , wherein the disease is hepatic fibrosis.

30 . The method of claim 17 , wherein the disease is renal fibrosis.

31 . The method of claim 17 , wherein the disease is pulmonary fibrosis.

Assignees

• Chugai Pharmaceutical Co Ltd
• Univ Jichi Medical
• Nat Inst Biomedical Innovation Health & Nutrition

Inventors

• Kakiuchi Ayako
• Kato Atsuhiko
• Hayashi Shuji
• Yanagisawa Izumi
• Konno Ryo
• Netsu Sachiho
• Sankai Tadashi

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K16/244 Primary

  Interleukins [IL] · CPC title

• A61K39/395 Primary

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• A61K45/00

  Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00 · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title